Abstract
Objectives Previous reports suggest a role of platelet derived growth factor (PDGF) in the development of cardiac allograft vasculopathy (CAV). The pharmaceutical blockade of tyrosine kinases may alter the expression of different growth factor receptors: platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) and hereby play a role in the context of cardiac allograft vasculopathy. Therefore the aim of this study was to determine the impact of tyrosine kinase inhibition on the development of cardiac allograft vasculopathy in a mouse model. Methods Fully allogeneic mouse aortas from C57BL/6 mice (H2b) were abdominally transplanted into CBA mice (H2k). Recipients were treated with tyrosine kinase inhibitor nintedanib (60mg/kg/d) and sacrificed on day 14 for cytokine PCR analysis of the graft or on day 30 for (immuno-) histological measurements. Results Aortic grafts treated with tyrosine kinase inhibitor nintedanib showed significantly reduced neointima proliferation (33% ± 12% vs. 54% ± 13%) after 30 days. These findings go along with significantly reduced amounts of smooth muscle cells (SMC) (20% ± 9% vs. 42% ± 10%) within the neointima. Further immunofluorescence analysis revealed no relevant difference in the percentages of dendritic cells, macrophages and CD4+ T-cells within the neointima. Meanwhile, the expression of both PDGF receptor subtypes α and β was reduced within the neointima of the aortic grafts. Additionally, we found a reduced gene expression of the ligand PDGF-B, a mitogen for SMC, and of the pro-inflammatory CD40L. Conclusion PDGF receptor blockade via inhibition of receptor tyrosine kinases seems to be a promising way to prevent the development of cardiac allograft vasculopathy in a mouse model. We would speculate a direct inhibition of the migration and proliferation of smooth muscle cells with a resulting decrease of neointima formation as the mechanism of action.
Full Text
Topics from this Paper
Development Of Cardiac Allograft Vasculopathy
Amounts Of Smooth Muscle Cells
Tyrosine Kinase Inhibitor Nintedanib
Murine Aortic Transplant Model
Mitogen For Smooth Muscle Cells
+ Show 5 more
Create a personalized feed of these topics
Get StartedTalk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
The American Journal of Pathology
Jul 1, 2009
The American Journal of Pathology
Nov 1, 2014
The American Journal of Pathology
May 1, 2013
Hepatology
Jan 1, 2007
The American Journal of Pathology
Oct 1, 2009
The Journal of Heart and Lung Transplantation
Apr 1, 2020
Structure
Aug 1, 2011
Kidney International
Jun 1, 2009
Journal of Biological Chemistry
Mar 1, 1998
Current Vascular Pharmacology
Sep 1, 2010
Journal of Biological Chemistry
Jul 1, 2001
Journal of Biological Chemistry
Aug 1, 1998
Journal of Biological Chemistry
Dec 1, 1995
Journal of Biological Chemistry
May 1, 1999
Transplantation
Transplantation
Nov 28, 2023
Transplantation
Nov 28, 2023
Transplantation
Nov 28, 2023
Transplantation
Nov 22, 2023
Transplantation
Nov 22, 2023
Transplantation
Nov 22, 2023
Transplantation
Nov 22, 2023
Transplantation
Nov 22, 2023
Transplantation
Nov 13, 2023
Transplantation
Nov 13, 2023